Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer. | Cell Stress | 2023 | 37970489 | PubTator, text mining | PubMed |
| Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses. | Explor Target Antitumor Ther | 2023 | 37970210 | PubTator, text mining | PubMed |
| A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer. | Eur J Med Res | 2023 | 37968767 | PubTator, text mining | PubMed |
| Single cell transcriptomics shows that malaria promotes unique regulatory responses across multiple immune cell subsets. | Nat Commun | 2023 | 37968278 | PubTator, text mining | PubMed |
| Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer. | Cell Discov | 2023 | 37968259 | PubTator, text mining | PubMed |
| Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. | Cell Rep Med | 2023 | 37967556 | PubTator, text mining | PubMed |
| Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review). | Oncol Lett | 2023 | 37965160 | PubTator, text mining | PubMed |
| Advances of Nanotechnology in the Diagnosis and Treatment of Hepatocellular Carcinoma. | J Clin Med | 2023 | 37959332 | PubTator, text mining | PubMed |
| Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target. | Cancers (Basel) | 2023 | 37958417 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. | Cancers (Basel) | 2023 | 37958409 | PubTator, text mining | PubMed |
| Memory regulatory T cells in pregnancy. | Front Immunol | 2023 | 37954599 | PubTator, text mining | PubMed |
Identification and validation of a novel signature based on T cell marker genes to predict prognosis, immunotherapy response and chemotherapy sensitivity in head and neck squamous carcinoma by integrated analysis of single-cell and bulk RNA-sequencing. | Heliyon | 2023 | 37954266 | PubTator, text mining | PubMed |
| Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients. | Nat Commun | 2023 | 37938561 | PubTator, text mining | PubMed |
| Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy. | Front Immunol | 2023 | 37936703 | PubTator, text mining | PubMed |
| Transcriptome profiling of regulatory T cells from children with transient hypogammaglobulinemia of infancy. | Clin Exp Immunol | 2023 | 37936298 | PubTator, text mining | PubMed |
| Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib. | Cancer Res Commun | 2023 | 37930123 | PubTator, text mining | PubMed |
| Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth. | Front Immunol | 2023 | 37928524 | PubTator, text mining | PubMed |
| IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy. | Front Immunol | 2023 | 37928523 | PubTator, text mining | PubMed |
| Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature. | J Cancer | 2023 | 37928426 | PubTator, text mining | PubMed |
| MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner. | J Exp Clin Cancer Res | 2023 | 37926835 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=15